• Last week, FDA announced the availability of a draft guidance for industry entitled, “Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271.” The draft guidance document provides certain establishments that manufacture non-reproductive human cells, tissues, and cellular and tissue-based products (HCT/Ps), regulated solely under the Public Health Service Act and under FDA regulations, with recommendations and relevant examples for complying with the requirements to report HCT/P deviations.
Pharmaceutical Consultants know Lean Pharma is Smart Consulting, but how do you apply Lean Manufacturing principles to the pharma lab with Quality, Compliance and batch size issues and the FDA? It Takes Smart Consulting To Make Pharma Work Better.
You know your business, but sometimes it takes a new pair of eyes, an “outside-the-box” viewpoint from an industry expert that knows smart Pharma lab operations inside out. A Consultant with experience across a wide range of Pharmaceutical areas, who brings you practical, usable, cost-effective solutions for YOUR particular needs.
20 E Market St West Chester, PA 19382 USA